• 1
    Christensen MM, Bruskewitz RC. Clinical manifestations of benign prostatic hyperplasia and indications for therapeutic intervention. Urol Clin North Am 1990; 17: 50916
  • 2
    Berry SJ, Coffey DS, Walsh PC et al. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 4749
  • 3
    McConnell JD, Bruskewitz R, Walsh P et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia; N Engl J Med 1998; 338: 55763
  • 4
    Mebust WK, Holtgrewe HL, Cockett AT et al. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3885 patients. J Urol 1989; 141: 2437
  • 5
    Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol 1984; 18: 4612
  • 6
    Descotes JL, Rambeaud JJ, Deschaseaux P et al. Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 1995; 9: 2917
  • 7
    Braeckman J, Denis L, De Leval J et al. A double-blind, placebo-controlled study of the plant extract Serenoa repens in the treatment of benign hyperplasia of the prostate. Eur J Clin Res 1997; 9: 24759
  • 8
    Carraro J-C, Raynaud J-P, Koch G et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomised international study of 1,098 patients. Prostate 1996; 29: 23140
  • 9
    Reece Smith H, Memon A, Smart CJ et al. The value of Permixon in benign prostatic hypertrophy. Br J Urol 1986; 58: 3640
  • 10
    Marks LS, Partin AW, Epstein JI et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 2000; 163: 14516
  • 11
    Mebust W, Roizo R, Schroder F et al. Correlations between pathology, clinical symptoms and the course of the disease. In Cockett ATK, Aso Y, Chatelain C et al. eds, Recommendations of the International Consultation on Benign Hyperplasia. Geneva: WHO, 1991: 5162
  • 12
    Kirby RS. The clinical assessment of benign prostatic hyperplasia. Cancer (Suppl) 1992; 70: 28490
  • 13
    Anonymous. The process of care consensus panel. The process of core model for evaluation and treatment of erectile dysfunction. Int J Impot Res 1999; 11: 5970
  • 14
    Wilt T, Ishani A, Stark G et al. Serenoa repens for treatment of benign prostatic hyperplasia (Cochrane Review). In: The Cochrane Library, Issue 1 1999. Oxford: Update Software
  • 15
    Braeckman J. The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Curr Therap Res; 1994; 55: 77685
  • 16
    Gerber GS, Zagaja GP, Bales GT et al. Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms. effects on urodynamic parameters and voiding symptoms. Urology; 1998; 51: 10037
  • 17
    Drew A. An alternative stream: Serenoa repens for benign prostatic hypertrophy? Aust Prescr 2000; 23: 79